A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya? (somapacitan) in adults with growth hormone deficiency (AGHD) under normal routine practice (REAL 7)
Description
We are doing this study to collect information about how safe and effective Sogroya ? (somapacitan) is, when used for treatment of people with Adult Growth Hormone Deficiency (AGHD) such as yourself. Sogroya ? (somapacitan), which is prescribed to you by your doctor. It is commercially available in your country as well as in many other countries and has been approved by regulatory authorities.
Details
Age
Adult
Eligibility
Diagnosis of Adult Growth Hormone Deficiency (AGHD).
Currently being treated or planned to start treatment with Sogroya? (somapacitan).
Locations
University of Colorado Hospital
Principal Investigator
Christie Turin more
Study ID
Protocol Number: 23-1727
More information available at ClinicalTrials.gov: NCT05718570
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers